jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Breast biopsy - Small <1cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

To determine if a small breast lesion is benign or malignant

₹280₹800

65% OFF

Breast Biopsy - Small (<1cm)

  • Why is it done?
    • To obtain tissue samples from small breast lesions (less than 1 centimeter) for microscopic examination and definitive diagnosis
    • To determine whether a small breast mass is benign (non-cancerous) or malignant (cancerous)
    • Indicated when imaging studies (mammography, ultrasound, or MRI) reveal small suspicious lesions that cannot be definitively characterized as benign
    • To evaluate microcalcifications, small nodules, or areas of architectural distortion detected on mammography
    • Commonly performed for BI-RADS 4-5 lesions (possibly malignant or highly suspicious for malignancy) requiring tissue diagnosis
    • Typically performed as an outpatient procedure using image-guided techniques (stereotactic, ultrasound-guided, or MRI-guided)
  • Normal Range
    • Normal/Benign Result: Tissue analysis shows normal breast tissue, fibroadenoma, lipoma, cyst, fat necrosis, or other clearly benign pathology
    • Negative for Malignancy: Histopathological examination reveals no evidence of cancerous cells or malignant features
    • Tissue Adequacy: Adequate number of representative tissue samples obtained to provide reliable diagnosis (typically 10-15 cores for core needle biopsy)
    • No Significant Atypia: Microscopic examination shows no suspicious cellular changes or architectural abnormalities
    • Abnormal Result: Presence of ductal carcinoma in situ (DCIS), invasive ductal/lobular carcinoma, atypical ductal hyperplasia (ADH), or other high-risk lesions
  • Interpretation
    • Benign Findings: Normal breast tissue, fibroadenomas, lipomas, or cysts require no further intervention; routine mammographic screening continues
    • High-Risk Lesions (ADH, ALH, LCIS): Associated with increased breast cancer risk; often warrant excisional biopsy to ensure complete removal and to assess for concurrent malignancy; close follow-up surveillance recommended
    • DCIS (Ductal Carcinoma In Situ): Noninvasive cancer confined to breast ducts; requires surgical excision with appropriate margins and potential radiation therapy
    • Invasive Carcinoma (IDC or ILC): Cancer cells invade beyond duct/lobule basement membrane; requires surgical excision, staging studies, and systemic therapy consideration based on tumor characteristics (grade, hormone receptor status, HER2 status)
    • Inadequate Tissue Sample: Insufficient material for diagnosis; repeat biopsy may be necessary using alternative technique or approach
    • Factors Affecting Interpretation: Proper tissue handling and fixation, pathologist expertise, adequate sampling, technical image guidance accuracy, and lesion accessibility all impact diagnostic reliability
  • Associated Organs
    • Primary Organ System: Breast tissue (mammary gland) and associated lymphatic system
    • Conditions Associated with Abnormal Results: Invasive breast cancer (ductal or lobular), ductal carcinoma in situ (DCIS), atypical hyperplasia, and high-risk proliferative lesions
    • Diseases Diagnosed or Monitored: Breast cancer (early detection), inflammatory breast disease, fibroadenomas, phyllodes tumors, papillomas, and other benign breast pathology
    • Potential Complications: Minor: Mild pain, bruising, swelling at biopsy site Rare: Infection, hematoma formation, vasovagal reaction, needle tract seeding (extremely rare) Biopsy-related anxiety and need for surgical follow-up if malignancy detected
    • Metastatic Potential: Malignant lesions can involve regional lymph nodes (axillary, supraclavicular, internal mammary) and distant organs; assessment of staging and prognosis depends on biopsy findings and subsequent imaging
  • Follow-up Tests
    • If Benign Findings: Routine mammographic screening at standard intervals (annual or biennial based on age/risk); short-term follow-up imaging (3-6 months) may be recommended for specific benign lesions to document stability
    • If High-Risk Lesions (ADH, ALH, LCIS) Detected: Excisional biopsy or surgical consultation for wider excision with margin assessment; enhanced surveillance imaging (MRI may be considered); genetic counseling if hereditary risk factors present
    • If DCIS or Invasive Carcinoma: Oncology referral, surgical consultation for lumpectomy or mastectomy, staging studies (CT chest/abdomen, bone scan if indicated), hormone receptor testing (ER/PR), HER2 testing, tumor grade and molecular profiling
    • Complementary Imaging Tests: Bilateral mammography with ultrasound, breast MRI for staging or detecting additional lesions, PET-CT if metastatic disease suspected
    • Inadequate Sample: Repeat biopsy using different imaging guidance (ultrasound, stereotactic, or MRI-guided) or excisional surgical biopsy to ensure definitive diagnosis
    • Genetic Testing: BRCA1/BRCA2 mutation testing if early-onset cancer or significant family history; multigene panel testing may be considered for treatment planning and surveillance
    • Long-term Surveillance: Ongoing mammographic surveillance every 6-12 months after malignancy diagnosis; follow-up appointments with oncology, breast surgeon, and imaging per treatment protocol
  • Fasting Required?
    • Fasting Required: No
    • Patient Preparation Instructions: Wear comfortable, loose-fitting clothing that can be easily removed Avoid applying deodorant, lotion, or powder to breasts on day of procedure Arrange transportation as sedation may be used Schedule biopsy in first half of menstrual cycle if possible (when breast tissue is less dense and tender) Bring insurance card and photo identification Expect procedure to take 15-30 minutes
    • Medication Considerations: Continue regular medications unless specifically instructed otherwise Avoid anticoagulants (warfarin, dabigatran) and high-dose aspirin/NSAIDs for 3-5 days prior if possible (consult with physician); continue anticoagulation for high-risk conditions per provider guidance Inform radiologist/physician of all medications, allergies, and bleeding disorders
    • Post-Procedure Care: Apply ice pack to biopsy site for 15-20 minutes to reduce swelling Wear supportive bra for comfort Take over-the-counter pain reliever if needed (acetaminophen or ibuprofen) Avoid strenuous activity for 24-48 hours Monitor biopsy site for excessive bleeding, severe swelling, or signs of infection Results typically available within 3-7 business days

How our test process works!

customers
customers